Adherence to Guidelines for Respiratory Syncytial Virus Immunoprophylaxis Among Infants with Prematurity or Chronic Lung Disease in Three United States Counties

Pediatric Infectious Disease Journal

Volumn 31, Issue 11, 2012, Pages e229-e231

  Carroll, Kecia N ^a   Griffin, Marie R ^a   Edwards, Kathryn M ^a   Ali, Asad ^a   Zhu, Yuwei ^a   Iwane, Marika K ^a   Szilagyi, Peter G ^a   Staat, Mary A ^a   Stevens, Timothy P ^a   Hall, Caroline B ^a   Williams, John V ^a   Hartert, Tina V ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Palivizumab; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; CHILD; CHRONIC LUNG DISEASE; HUMAN; IMMUNOPROPHYLAXIS; INFANT; INFANT DISEASE; MAJOR CLINICAL STUDY; PARAMYXOVIRUS INFECTION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS INFECTION; UNITED STATES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; CHRONIC DISEASE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; PRACTICE GUIDELINES AS TOPIC; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; TIME FACTORS; UNITED STATES;

EID: 84867891144     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318266bf89     Document Type: Article

References (12)

1. Stockman LJ, Curns AT, Anderson LJ, et al. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J. 2012;31:5-9
2. Boyce TG, Mellen BG, Mitchel EF Jr, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000;137:865-870
3. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537
4. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102:1211-1216
5. American Academy of Pediatrics Committee on Infectious Diseases. Red Book: Report of the Committee on Infectious Diseases. 200627th ed Elk Grove Village, IL American Academy of Pediatrics
6. American Academy of Pediatrics Committee on Infectious Diseases and Commitee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112:1442-1446
7. Griffin MR, Walker FJ, Iwane MK, et al.New Vaccine Surveillance Network Study Group. Epidemiology of respiratory infections in young children: insights from the new vaccine surveillance network. Pediatr Infect Dis J. 2004;23(11 suppl):S188-S192
8. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588-598
9. Neuzil KM, Reed GW, Mitchel EF, et al. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol. 1998;148:1094-1102
10. Hampp C, Saidi AS, Winterstein AG. Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida. J Pediatr. 2010;156:953-9, 959.e1
11. Afghani B, Ngo T, Leu SY, et al. The effect of an interventional program on adherence to the american academy of pediatrics guidelines for palivizumab prophylaxis. Pediatr Infect Dis J. 2006;25:1019-1024
12. Frogel MP, Stewart DL, Hoopes M, et al. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm. 2010;16:46-58